A study to evaluate the efficacy of Intensity Modulated Radiation Therapy (IMRT) as compared to Standard Conventional Radiotherapy Alone in the treatment of carcinoma cervix. Concomitant Weekly Cisplatin chemotherapy will be given as a routine, which is a standard of care today for early stage cervical cancers including stage IIB. The benefits of using IMRT in reducing radiation-induced toxicity are well known. Since this treatment modality has not yet been validated and studied in a randomized trial setting, the present study is being undertaken. The study arm of IMRT has the potential to reduce the toxicities by 15-20%, but is associated with labor intense procedure requiring many hospital visits before actual start of treatment.

Patients with histologically proven cervical cancers, FIGO Stage IIb eligible for the study will be invited for the study

Criteria

Inclusion Criteria:

Histologically proven squamous carcinoma or adenocarcinoma of cervix

Performance index WHO grade 0 or 1

Patients below 65 years of age

FIGO Stage IIB

Normal ECG and Cardiovascular system

Normal hematological parameters

Normal renal and liver function tests

Exclusion Criteria:

Co-morbid conditions like medical renal disease

Medical or Psychological condition that would preclude treatment

H/o Previous treatment / Pregnancy

Patient unreliable for treatment completion and follow-up.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00193804